Mini-Sentinel: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive Analysis

Basic Details
Date Posted
Monday, November 9, 2020
Status
Complete
Medical Product
saxagliptin
sitagliptin
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
sulfonylurea
Health Outcome(s)
diabetic ketoacidosis
Description

In this request we estimated the rate of diabetic ketoacidosis (DKA) among new users of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas, saxagliptin, and sitagliptin in the Mini-Sentinel Distributed Database (MSDD). We distributed this request to 13 Data Partners on June 26, 2015. The study period included data from April 1, 2013 to March 31, 2015.

Additional Details
FDA Center
CDER
Time Period
April 1, 2013 - March 31, 2015
Study Type
Modular Program
Assessment Type
Safety Analyses
Population / Cohort
All individuals
Data Sources
Mini-Sentinel Distributed Dataset (MSDD)